Anavex Life Sciences Corp
$ 2.57
2.80%
28 Jul - close price
- Market Cap 231,679,000 USD
- Current Price $ 2.57
- High / Low $ 2.60 / 2.47
- Stock P/E N/A
- Book Value 1.37
- EPS -0.46
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.34 %
- 52 Week High 12.68
- 52 Week Low 2.25
About
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
Analyst Target Price
$20.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-06-23 | 2026-02-09 | 2025-11-25 | 2025-08-12 | 2025-05-13 | 2025-02-12 | 2024-12-23 | 2024-08-06 | 2024-05-09 | 2024-02-07 | 2023-11-27 | 2023-08-08 |
| Reported EPS | -0.13 | -0.06 | -0.11 | -0.16 | -0.13 | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 |
| Estimated EPS | -0.07 | -0.11 | -0.1426 | -0.14 | -0.15 | -0.17 | -0.17 | -0.18 | -0.13 | -0.15 | -0.15 | -0.17 |
| Surprise | -0.06 | 0.05 | 0.0326 | -0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0 | 0.04 | 0.03 | 0.03 |
| Surprise Percentage | -85.7143% | 45.4545% | 22.8612% | -14.2857% | 13.3333% | 17.6471% | 17.6471% | 22.2222% | 0% | 26.6667% | 20% | 17.6471% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVXL
2026-07-27 15:11:33
This article provides an overview of Anavex Life Sciences Corp (AVXL) regarding its dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock performance data, market capitalization, and links to various company-related financial and analytical information.
2026-07-25 21:41:18
Anavex Life Sciences Corp. (AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system diseases. The article provides an overview of the company's profile, including its core programs ANAVEX 2-73 and ANAVEX 3-71, and lists key executives and institutional shareholding data.
2026-07-25 17:41:57
This page provides financial information for Anavex Life Sciences Corp. (SWB:12X1) listed on the Stuttgart Stock Exchange. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub to various financial data points rather than a detailed news article.
2026-07-24 15:10:24
PVG Asset Management Corporation and Patrick S. Adams are launching an activist proxy solicitation to replace the entire Board of Directors at Anavex Life Sciences (NASDAQ: AVXL) with six independent nominees during the 2026 annual meeting. The activist group, collectively owning 327,344 shares of Anavex common stock, is advocating for the change due to concerns over value destruction, leadership changes, investor relations, and regulatory non-compliance, including a Nasdaq delinquency notification. They aim to elect their slate of directors using a GOLD universal proxy card, asserting that the current board has failed to protect shareholder interests.
2026-07-20 13:11:33
Anavex Life Sciences (AVXL) submitted a Compliance Plan to Nasdaq following a late Form 10-Q filing for the quarter ended March 31, 2026. The company aims to regain compliance with Nasdaq Rule 5250(c)(1) and seek reinstatement of its listing. While the deficiency notice does not immediately affect its trading on the Nasdaq Global Select Market, acceptance of the plan could lead to an extension, while rejection may result in a hearing.
2026-07-20 12:32:00
Anavex Life Sciences Corp. has submitted a plan to Nasdaq to regain compliance with the exchange's timely filing rule. This action follows previous notifications of delinquency from Nasdaq. The company is focused on developing treatments for various central nervous system diseases.
